181 related articles for article (PubMed ID: 16365179)
1. Tumor necrosis factor-alpha-induced protein 3 as a putative regulator of nuclear factor-kappaB-mediated resistance to O6-alkylating agents in human glioblastomas.
Bredel M; Bredel C; Juric D; Duran GE; Yu RX; Harsh GR; Vogel H; Recht LD; Scheck AC; Sikic BI
J Clin Oncol; 2006 Jan; 24(2):274-87. PubMed ID: 16365179
[TBL] [Abstract][Full Text] [Related]
2. miR-125b controls apoptosis and temozolomide resistance by targeting TNFAIP3 and NKIRAS2 in glioblastomas.
Haemmig S; Baumgartner U; Glück A; Zbinden S; Tschan MP; Kappeler A; Mariani L; Vajtai I; Vassella E
Cell Death Dis; 2014 Jun; 5(6):e1279. PubMed ID: 24901050
[TBL] [Abstract][Full Text] [Related]
3. A20 inhibits human salivary adenoid cystic carcinoma cells invasion via blocking nuclear factor-kappaB activation.
Zhang B; Guan CC; Chen WT; Zhang P; Yan M; Shi JH; Qin CL; Yang Q
Chin Med J (Engl); 2007 Oct; 120(20):1830-5. PubMed ID: 18028781
[TBL] [Abstract][Full Text] [Related]
4. Nuclear factor-kappaB regulates beta-cell death: a critical role for A20 in beta-cell protection.
Liuwantara D; Elliot M; Smith MW; Yam AO; Walters SN; Marino E; McShea A; Grey ST
Diabetes; 2006 Sep; 55(9):2491-501. PubMed ID: 16936197
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of nuclear factor-kappaB activity by temozolomide involves O6-methylguanine induced inhibition of p65 DNA binding.
Yamini B; Yu X; Dolan ME; Wu MH; Darga TE; Kufe DW; Weichselbaum RR
Cancer Res; 2007 Jul; 67(14):6889-98. PubMed ID: 17638900
[TBL] [Abstract][Full Text] [Related]
6. Functional dichotomy of A20 in apoptotic and necrotic cell death.
Storz P; Döppler H; Ferran C; Grey ST; Toker A
Biochem J; 2005 Apr; 387(Pt 1):47-55. PubMed ID: 15527421
[TBL] [Abstract][Full Text] [Related]
7. MSH6 mutations arise in glioblastomas during temozolomide therapy and mediate temozolomide resistance.
Yip S; Miao J; Cahill DP; Iafrate AJ; Aldape K; Nutt CL; Louis DN
Clin Cancer Res; 2009 Jul; 15(14):4622-9. PubMed ID: 19584161
[TBL] [Abstract][Full Text] [Related]
8. A20 expressing tumors and anticancer drug resistance.
da Silva CG; Minussi DC; Ferran C; Bredel M
Adv Exp Med Biol; 2014; 809():65-81. PubMed ID: 25302366
[TBL] [Abstract][Full Text] [Related]
9. A20/TNFAIP3, a new estrogen-regulated gene that confers tamoxifen resistance in breast cancer cells.
Vendrell JA; Ghayad S; Ben-Larbi S; Dumontet C; Mechti N; Cohen PA
Oncogene; 2007 Jul; 26(32):4656-67. PubMed ID: 17297453
[TBL] [Abstract][Full Text] [Related]
10. Ebselen sensitizes glioblastoma cells to Tumor Necrosis Factor (TNFalpha)-induced apoptosis through two distinct pathways involving NF-kappaB downregulation and Fas-mediated formation of death inducing signaling complex.
Sharma V; Tewari R; Sk UH; Joseph C; Sen E
Int J Cancer; 2008 Nov; 123(9):2204-12. PubMed ID: 18709644
[TBL] [Abstract][Full Text] [Related]
11. SGEF Is Regulated via TWEAK/Fn14/NF-κB Signaling and Promotes Survival by Modulation of the DNA Repair Response to Temozolomide.
Ensign SP; Roos A; Mathews IT; Dhruv HD; Tuncali S; Sarkaria JN; Symons MH; Loftus JC; Berens ME; Tran NL
Mol Cancer Res; 2016 Mar; 14(3):302-12. PubMed ID: 26764186
[TBL] [Abstract][Full Text] [Related]
12. NF-kappaB-independent sensitization of glioblastoma cells for TRAIL-induced apoptosis by proteasome inhibition.
La Ferla-Brühl K; Westhoff MA; Karl S; Kasperczyk H; Zwacka RM; Debatin KM; Fulda S
Oncogene; 2007 Jan; 26(4):571-82. PubMed ID: 16909119
[TBL] [Abstract][Full Text] [Related]
13. Cytoplasmic TRADD confers a worse prognosis in glioblastoma.
Chakraborty S; Li L; Tang H; Xie Y; Puliyappadamba VT; Raisanen J; Burma S; Boothman DA; Cochran B; Wu J; Habib AA
Neoplasia; 2013 Aug; 15(8):888-97. PubMed ID: 23908590
[TBL] [Abstract][Full Text] [Related]
14. MicroRNAs miR-125a and miR-125b constitutively activate the NF-κB pathway by targeting the tumor necrosis factor alpha-induced protein 3 (TNFAIP3, A20).
Kim SW; Ramasamy K; Bouamar H; Lin AP; Jiang D; Aguiar RC
Proc Natl Acad Sci U S A; 2012 May; 109(20):7865-70. PubMed ID: 22550173
[TBL] [Abstract][Full Text] [Related]
15. MGMT promoter methylation correlates with survival benefit and sensitivity to temozolomide in pediatric glioblastoma.
Donson AM; Addo-Yobo SO; Handler MH; Gore L; Foreman NK
Pediatr Blood Cancer; 2007 Apr; 48(4):403-7. PubMed ID: 16609952
[TBL] [Abstract][Full Text] [Related]
16. A DNA methylation prognostic signature of glioblastoma: identification of NPTX2-PTEN-NF-κB nexus.
Shukla S; Pia Patric IR; Thinagararjan S; Srinivasan S; Mondal B; Hegde AS; Chandramouli BA; Santosh V; Arivazhagan A; Somasundaram K
Cancer Res; 2013 Nov; 73(22):6563-73. PubMed ID: 24078801
[TBL] [Abstract][Full Text] [Related]
17. Combined expression of A1 and A20 achieves optimal protection of renal proximal tubular epithelial cells.
Kunter U; Daniel S; Arvelo MB; Choi J; Shukri T; Patel VI; Longo CR; Scali ST; Shrikhande G; Rocha E; Czismadia E; Mottley C; Grey ST; Floege J; Ferran C
Kidney Int; 2005 Oct; 68(4):1520-32. PubMed ID: 16164629
[TBL] [Abstract][Full Text] [Related]
18. Adenovirus-mediated expression of a dominant negative mutant of p65/RelA inhibits proinflammatory gene expression in endothelial cells without sensitizing to apoptosis.
Soares MP; Muniappan A; Kaczmarek E; Koziak K; Wrighton CJ; Steinhäuslin F; Ferran C; Winkler H; Bach FH; Anrather J
J Immunol; 1998 Nov; 161(9):4572-82. PubMed ID: 9794384
[TBL] [Abstract][Full Text] [Related]
19. A20 is a potent inhibitor of TLR3- and Sendai virus-induced activation of NF-kappaB and ISRE and IFN-beta promoter.
Wang YY; Li L; Han KJ; Zhai Z; Shu HB
FEBS Lett; 2004 Oct; 576(1-2):86-90. PubMed ID: 15474016
[TBL] [Abstract][Full Text] [Related]
20. O6-methylguanine DNA methyltransferase and p53 status predict temozolomide sensitivity in human malignant glioma cells.
Hermisson M; Klumpp A; Wick W; Wischhusen J; Nagel G; Roos W; Kaina B; Weller M
J Neurochem; 2006 Feb; 96(3):766-76. PubMed ID: 16405512
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
